Bio & Pharma
SillaJen starts US trial of anti-cancer drug from Basilea
The South Korean biotechnology firm plans to evaluate the safety and optimal dose of BAL0891 in phase 1 trial
By Feb 27, 2023 (Gmt+09:00)
1
Min read
Most Read
Macquarie eyes its 1st Korean data center valued around $722 mn
S.Korea's LS Materials set to boost earnings ahead of IPO process
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
POSCO gears up for carbon-free steelmaking with hydrogen
SillaJen Inc. said on Monday it has enrolled the first patient in a US phase 1 trial of an anti-cancer drug BAL0891 licensed from Swiss drugmaker Basilea Pharmaceutica Ltd.
The South Korean biotechnology company acquired the exclusive rights to develop and commercialize the drug, a mitotic checkpoint inhibitor (MCI), in September last year.
In phase 1, SillaJen plans to evaluate the safety and optimal dose of BAL0891 by intravenously administering it to patients with metastatic solid tumors. It also plans to start a trial of combining the drug with paclitaxel, an existing anti-cancer agent.
SillaJen said it would conduct the same trial in Korea as well.
A SillaJen official said the company aims to boost its technology exports based on the research data from the US phase 1 trial.
Write to Yoorim Kim at youforest@hankyung.com
More to Read
-
Bio & PharmaS. Korea's SillaJen launches clinical trials in US for new anti-cancer drug
Dec 14, 2022 (Gmt+09:00)
1 Min read -
Bio & PharmaSillaJen shares jump as exchange maintains listing, allows resumed trade
Oct 13, 2022 (Gmt+09:00)
2 Min read
Comment 0
LOG IN